Merck Kgaa Dm 5 (MKGAF) 102.8500 $MKGAF Merck KGaA's Q1

New Post Public Reply Private Reply Replies (0) Message Board

Jun 9, 2016 at 10:07 AM

Merck Kgaa Dm 5 (MKGAF) 102.8500 $MKGAF

Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 84.46 (+0.36), PFE: 35.42 (+0.17), BMY: 73.65 (+0.24)

Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.

Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 15.12 (+0.17), BMRN: 84.46 (+0.36), PFE: 35.42 (+0.17)

Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 1.24 (-0.02), ANIP: 55.95 (+0.15), XON: 26.00 (-0.50)

Merck KGaA's Q4 Earnings Down Y/Y, Offers 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:20AM CST
Merck KGaA (MKGAF) reported fourth-quarter 2015 earnings of 32 cents, down 60.2% from the year over year.
GILD: 86.73 (-0.69), PFE: 35.42 (+0.17), HZNP: 18.73 (+0.19)

Merck KGaA (MKGAF) Q4 Earnings Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:02AM CST
Merck KGaA (MKGAF) fourth-quarter 2015 earnings per American Depositary Receipt (ADR) came in at 32 cents.

What Awaits Merck KGaA (MKGAF) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:40AM CST
Merck KGaA (MKGAF) will be reporting its fourth-quarter 2015 earnings results on Mar 8.
BDSI: 2.86 (-0.06), BMRN: 84.46 (+0.36), PFE: 35.42 (+0.17)

Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.57 (-0.03), SNDX: 14.00 (-0.24), PFE: 35.42 (+0.17)

Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 35.42 (+0.17), HZNP: 18.73 (+0.19), ARNA: 2.14 (-0.01)

Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 9.73 (+0.12), PFE: 35.42 (+0.17), ANIK: 48.91 (+0.19)

Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 9.73 (+0.12), PFE: 35.42 (+0.17), ANIK: 48.91 (+0.19)

Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 57.71 (+0.09), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 250.44 (+0.49), PFE: 35.42 (+0.17), LLY: 75.46 (+0.55)

Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 26.00 (-0.50), BXLT: 46.02 (-0.18), ANIK: 48.91 (+0.19)

Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 57.71 (+0.09), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 18.10 (+0.38), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 84.46 (+0.36), NVET: 4.27 (+0.26), REGN: 389.77 (+0.80)

Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 35.42 (+0.17), LLY: 75.46 (+0.55), NVS: 81.03 (-0.36)

Merck KGaA Continues Restructuring Efforts, Growth in Focus
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 8:40AM CDT
Merck KGaA (MKGAF) continues with its efforts to simplify the company's organizational structure and focus on the growth trajectory of the Healthcare business.
VRX: 24.67 (+0.75), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

High-Grade Copper Spurs Optimism for PolarX in Alaska

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...